HealthEquity (NASDAQ:HQY) Upgraded at Wall Street Zen

HealthEquity (NASDAQ:HQY) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other equities analysts have also issued reports on the company. Barclays reduced their price target on HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft raised their price target on HealthEquity from $120.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Raymond James Financial set a $100.00 price target on HealthEquity in a research report on Tuesday, February 17th. Citizens Jmp raised their price target on HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research report on Monday, June 1st. Finally, Royal Bank Of Canada raised their price target on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, HealthEquity presently has a consensus rating of “Moderate Buy” and an average target price of $110.57.

HealthEquity Price Performance

Shares of HealthEquity stock opened at $88.67 on Friday. The company has a current ratio of 3.44, a quick ratio of 3.44 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $7.41 billion, a PE ratio of 33.21, a price-to-earnings-growth ratio of 1.47 and a beta of 0.21. The business’s 50-day moving average price is $84.05 and its 200-day moving average price is $86.33. HealthEquity has a 12 month low of $72.76 and a 12 month high of $113.80.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Thursday, May 28th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.11 by $0.13. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm had revenue of $354.64 million for the quarter, compared to analyst estimates of $352.02 million. HealthEquity’s revenue for the quarter was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts forecast that HealthEquity will post 3.86 EPS for the current fiscal year.

Insiders Place Their Bets

In other HealthEquity news, EVP Michael Henry Fiore sold 3,142 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $95.00, for a total value of $298,490.00. Following the completion of the sale, the executive vice president owned 59,113 shares in the company, valued at approximately $5,615,735. This trade represents a 5.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Following the completion of the sale, the executive vice president owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This trade represents a 7.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,081 shares of company stock worth $1,193,000. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On HealthEquity

Institutional investors and hedge funds have recently bought and sold shares of the business. Capricorn Fund Managers Ltd purchased a new stake in HealthEquity in the 4th quarter worth approximately $6,926,000. 12th Street Asset Management Company LLC lifted its holdings in HealthEquity by 114.4% in the 3rd quarter. 12th Street Asset Management Company LLC now owns 272,068 shares of the company’s stock worth $25,784,000 after buying an additional 145,151 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in HealthEquity by 45.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 155,543 shares of the company’s stock worth $14,741,000 after buying an additional 48,621 shares during the period. King Luther Capital Management Corp lifted its stake in shares of HealthEquity by 60.6% in the 3rd quarter. King Luther Capital Management Corp now owns 80,584 shares of the company’s stock valued at $7,637,000 after purchasing an additional 30,394 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of HealthEquity by 11.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,205,077 shares of the company’s stock valued at $114,205,000 after purchasing an additional 124,283 shares during the period. Hedge funds and other institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.